Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of once-weekly RO7795068 in Chinese adults with obesity or overweight with or without type 2 diabetes
CTR20262063Phase 3Active
- Sponsor
- Roche
- Start
- Jul 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of zilebesiran in obesity, Overweight, type 2 diabetes mellitus (T2DM), sponsored by Roche. Started Jul 2026; status: active.
02
Drugs
zilebesiran
03
Conditions
obesityOverweighttype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20262063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262063.